Form 4: Adaptive Biotechnologies CEO Sells Shares Under 10b5-1 Plan

Adaptive Biotechnologies CEO and Chairman Chad M. Robins sold 124,998 shares of common stock for a weighted average price of $15.59 per share, executed under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Chad M. Robins, CEO and Chairman of Adaptive Biotechnologies Corp (ADPT), reported a sale of common stock.
• The transaction involved the disposition of 124,998 shares of common stock on January 5, 2026.
• The shares were sold at a weighted average price of $15.59 per share, with individual transaction prices ranging from $15.31 to $15.96.
• This sale was conducted pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robins on August 11, 2025.
• Following this transaction, Mr. Robins beneficially owns 2,584,243 shares of common stock directly.

Sentiment

Score: 5

Explanation: The sale of shares by the CEO is generally viewed neutrally to slightly negatively. However, the execution under a pre-arranged Rule 10b5-1 plan mitigates concerns that the sale is based on new, undisclosed negative information, making the overall sentiment neutral.

Positives

• The transaction was executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned sale rather than a reaction to new, undisclosed information.

Negatives

• The CEO and Chairman sold a significant number of shares (124,998), which can sometimes be perceived as a negative signal by investors, even when pre-planned.

Risks

• Potential for negative investor sentiment if the market interprets the insider sale as a lack of confidence, despite the 10b5-1 plan.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: May interpret the insider sale as a signal, though the 10b5-1 plan suggests it is for personal financial planning rather than a reaction to company performance.

Key Dates

Keywords

Adaptive Biotechnologies, ADPT, Chad M. Robins, Insider Sale, Form 4, 10b5-1 Plan, CEO, Common Stock